AMINOLEVULINIC ACID HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Nxdc	GLEOLAN	aminolevulinic acid hydrochloride	FOR SOLUTION;ORAL	208630	NDA	Medexus Pharma, Inc.	59137-231-01	1 VIAL, SINGLE-DOSE in 1 CARTON (59137-231-01) / 1 POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2018-04-14
Nxdc	GLEOLAN	aminolevulinic acid hydrochloride	FOR SOLUTION;ORAL	208630	NDA	NX DEVELOPMENT CORP	71469-231-01	1 VIAL, SINGLE-DOSE in 1 CARTON (71469-231-01) / 1 POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2018-03-14
Biofrontera	AMELUZ	aminolevulinic acid hydrochloride	GEL;TOPICAL	208081	NDA	Biofrontera Inc.	70621-101-10	1 TUBE in 1 PACKAGE (70621-101-10) / 2 g in 1 TUBE (70621-101-01)	2016-08-26
Biofrontera	AMELUZ	aminolevulinic acid hydrochloride	GEL;TOPICAL	208081	NDA	Biofrontera Inc.	70621-101-20	10 TUBE in 1 PACKAGE (70621-101-20) / 2 g in 1 TUBE (70621-101-01)	2016-08-26
Biofrontera	AMELUZ	aminolevulinic acid hydrochloride	GEL;TOPICAL	208081	NDA	Biofrontera Inc.	70621-101-30	1 TUBE in 1 PACKAGE (70621-101-30) / 2 g in 1 TUBE (70621-101-03)	2016-08-26
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965	NDA	Sun Pharmaceutical Industries, Inc	67308-101-01	1 KIT in 1 APPLICATOR (67308-101-01) * 1.5 mL in 1 AMPULE * 1.5 mL in 1 AMPULE	2000-09-04
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965	NDA	Sun Pharmaceutical Industries, Inc	67308-101-02	2 APPLICATOR in 1 CARTON (67308-101-02) / 1 KIT in 1 APPLICATOR (67308-101-01) * 1.5 mL in 1 AMPULE * 1.5 mL in 1 AMPULE	2000-09-04
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Aminolevulinic acid hydrochloride (ALA HCl) is a photodynamic precursor used in medical diagnostics and therapeutics, primarily for the detection and treatment of various cancers. The market for ALA HCl is driven by its increasing adoption in photodynamic therapy (PDT) and photodynamic diagnosis (PDD). Key suppliers operate within a dynamic intellectual property environment, characterized by patent filings related to manufacturing processes, novel formulations, and therapeutic applications.

What is the Current Market Size and Projected Growth for Aminolevulinic Acid Hydrochloride?

The global market for aminolevulinic acid hydrochloride was valued at approximately $150 million in 2023 and is projected to reach $300 million by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5% [1]. This growth is attributed to the expanding use of ALA HCl in oncology for procedures like photodynamic therapy and diagnosis, particularly in treating skin cancers, bladder cancer, and certain gastrointestinal malignancies. The increasing prevalence of these diseases and advancements in PDT/PDD technologies are key market drivers. The market is segmented by application (photodynamic diagnosis, photodynamic therapy), end-user (hospitals, clinics, research institutions), and region. Asia-Pacific is expected to witness the highest growth due to a rising cancer incidence and growing healthcare infrastructure [1, 2].

Who are the Key Manufacturers and Suppliers of Aminolevulinic Acid Hydrochloride?

Several companies globally produce and supply ALA HCl. These suppliers range from large pharmaceutical ingredient manufacturers to specialized chemical producers. Key players include:

China Isotope & Radiation Corp (CIRCC): A significant producer with a substantial share in the global ALA HCl market, particularly serving the Asian market [3].
AbbVie Inc. (through its acquisition of Allergan): While primarily known for its finished drug products utilizing ALA HCl (e.g., Gleolan), AbbVie indirectly influences the supply chain through its demand and proprietary formulations [4].
Nippon Oil & Fats Co., Ltd. (NOF Corporation): A Japanese chemical company that manufactures ALA HCl and related derivatives, supplying to pharmaceutical companies for various applications [5].
Hubei Guangji Pharmaceutical Co., Ltd.: A major Chinese pharmaceutical ingredient manufacturer with ALA HCl as a key product, supplying both domestic and international markets [6].
Xi'an Lycoming Bio-Technology Co., Ltd.: A Chinese supplier focusing on pharmaceutical intermediates and active pharmaceutical ingredients, including ALA HCl.
Shaanxi Dongfang Pharmaceutical Co., Ltd.: Another Chinese manufacturer that produces and exports ALA HCl.

These suppliers often adhere to stringent Good Manufacturing Practice (GMP) standards to ensure product quality and compliance for pharmaceutical use [3, 6]. The supply chain is competitive, with pricing influenced by production scale, raw material costs, and regulatory compliance.

What are the Dominant Patent Areas for Aminolevulinic Acid Hydrochloride?

The patent landscape for ALA HCl is multifaceted, covering its synthesis, therapeutic applications, and delivery systems. Analysis of recent patent filings reveals several dominant areas:

Synthesis and Manufacturing Processes: Patents in this category focus on optimizing the chemical synthesis of ALA HCl to improve yield, reduce impurities, and lower production costs. This includes novel synthetic routes, improved catalysts, and purification techniques. For example, patents describe enzymatic synthesis methods or modifications to existing chemical synthesis pathways to achieve higher purity levels [7].
Therapeutic Applications: A significant portion of patent activity is directed towards new medical uses of ALA HCl. This includes its application in treating various cancers (e.g., glioblastoma, non-small cell lung cancer, prostate cancer), precancerous lesions, and certain dermatological conditions [8, 9]. Patents often define specific dosage regimens, treatment protocols, and combination therapies involving ALA HCl.
Formulations and Delivery Systems: Innovation in how ALA HCl is administered is another key patent area. This encompasses topical formulations (creams, gels, solutions), oral formulations, and novel delivery systems designed to enhance absorption, target specific tissues, or reduce side effects. Patents may describe microencapsulation techniques, liposomal delivery, or nano-carrier systems for improved efficacy [10].
Combination Therapies: Patents are being filed for combinations of ALA HCl with other therapeutic agents, including chemotherapeutic drugs, immunotherapies, and radiation therapy, to achieve synergistic effects in cancer treatment [11].

The geographical distribution of patent filings indicates strong activity in the United States, Europe, and China, reflecting the major markets and R&D hubs for pharmaceutical innovation.

How Do Patents Affect the Availability and Cost of Aminolevulinic Acid Hydrochloride?

Patents play a crucial role in shaping the commercial landscape for ALA HCl.

Exclusivity and Market Entry: Granted patents provide their holders with exclusive rights to their inventions for a defined period (typically 20 years from filing). This exclusivity can restrict other companies from manufacturing, using, or selling the patented ALA HCl product or process. Consequently, this limits the number of suppliers for patented innovations, potentially reducing overall market competition in the short to medium term for those specific patented technologies [12].
Pricing Influence: During the patent term, the innovator company can command premium pricing for its ALA HCl-based products or processes due to the lack of direct competition for that specific patented invention. This can lead to higher costs for healthcare providers and patients compared to generic alternatives that might emerge after patent expiry [13].
R&D Investment and Innovation: The prospect of patent protection incentivizes significant investment in research and development by pharmaceutical companies and research institutions. The ability to secure patent rights for novel synthesis methods, drug formulations, or new therapeutic uses encourages continued innovation in the ALA HCl field, leading to the development of more effective and safer treatments [12].
Generic Competition and Price Erosion: Upon patent expiry, generic manufacturers can enter the market, producing and selling bioequivalent ALA HCl products or utilizing off-patent manufacturing processes. This typically leads to a significant reduction in pricing due to increased competition, making treatments more accessible [13]. For example, as patents on early ALA HCl PDT formulations expire, more cost-effective treatment options become available.

The current patent landscape suggests ongoing innovation, particularly in novel therapeutic applications and advanced delivery systems, which will continue to influence market dynamics and pricing strategies.

What are the Key Regulatory Considerations for ALA HCl Suppliers?

Suppliers of ALA HCl must navigate a complex regulatory environment to ensure product quality, safety, and market access. Key considerations include:

Good Manufacturing Practices (GMP): Manufacturers must adhere to stringent GMP guidelines set by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan [14]. GMP compliance ensures that ALA HCl is consistently produced and controlled according to quality standards appropriate for its intended use as a pharmaceutical ingredient or medical device component. This involves rigorous control over raw materials, manufacturing processes, facility maintenance, and quality control testing.
Drug Master Files (DMFs): Suppliers often submit DMFs to regulatory agencies. A DMF is a submission to the FDA that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their drug applications without having direct access to proprietary manufacturing information [15].
Pharmacopeial Standards: ALA HCl must meet the quality specifications outlined in major pharmacopeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) [16]. These compendia define tests, procedures, and acceptance criteria for identity, strength, quality, and purity of drug substances. Suppliers must ensure their product conforms to these monograph requirements.
International Conference on Harmonisation (ICH) Guidelines: Compliance with ICH guidelines, such as those pertaining to quality (e.g., ICH Q7 for Active Pharmaceutical Ingredients), is essential for global market access. ICH guidelines provide a framework for harmonizing technical requirements in the pharmaceutical industry across different regions [17].
Product Registration and Marketing Authorization: For ALA HCl used in finished drug products or medical devices, the final product requires marketing authorization from relevant health authorities. Suppliers play a critical role in providing the necessary quality and safety data to support these applications [14]. The specific regulatory pathway depends on whether ALA HCl is considered an Active Pharmaceutical Ingredient (API) or a component of a medical device.

Navigating these regulatory requirements is essential for suppliers to maintain market access and ensure the safety and efficacy of ALA HCl for patient use.

What are the Future Trends and Opportunities in the ALA HCl Market?

The ALA HCl market is poised for continued evolution, with several key trends and opportunities emerging:

Expansion into New Cancer Indications: Research is ongoing to explore ALA HCl's efficacy in treating a broader spectrum of cancers, including pancreatic cancer, esophageal cancer, and head and neck cancers. Successful clinical trials in these areas will open new markets for ALA HCl [9].
Advancements in PDT/PDD Technology: Development of more sophisticated light sources (e.g., LED arrays, laser systems with specific wavelengths), improved imaging techniques for PDD, and optimized light dosimetry will enhance the effectiveness and utility of ALA HCl-based treatments [18].
Development of Targeted Delivery Systems: Future innovation will focus on creating delivery systems that further enhance the tumor-targeting capabilities of ALA HCl, minimizing off-target effects and improving therapeutic outcomes. This includes nanoparticle-based delivery and antibody-drug conjugates [10].
Combinatorial Therapies: The synergistic potential of ALA HCl with emerging treatments like immunotherapy and targeted molecular therapies represents a significant opportunity. Research into these combinations could lead to more robust and personalized treatment strategies [11].
Non-Oncological Applications: While oncology is the primary focus, emerging research suggests potential applications for ALA HCl in treating non-oncological conditions, such as certain inflammatory diseases and infections, which could diversify market demand [19].
Biologics and Biosimilars Landscape: As patents on ALA HCl-related technologies expire, there may be increased activity in developing biosimilar versions if ALA HCl is produced via biotechnological routes, or generic versions of drug products containing ALA HCl. This could increase competition and reduce prices for certain applications [13].

These trends underscore the dynamic nature of the ALA HCl market, offering substantial opportunities for companies involved in its development, manufacturing, and application.

Key Takeaways

The ALA HCl market is experiencing robust growth, projected to double by 2030, driven by its expanding use in cancer diagnostics and photodynamic therapy.
Key global suppliers are concentrated in Asia, with significant players in China and Japan, alongside major pharmaceutical entities indirectly influencing the supply chain.
Patent protection is a critical factor, with innovation focused on synthesis, novel therapeutic applications, and advanced delivery systems, influencing market entry and pricing.
Stringent regulatory compliance, including GMP, pharmacopeial standards, and DMF submissions, is mandatory for ALA HCl suppliers.
Future opportunities lie in exploring new cancer indications, enhancing PDT/PDD technologies, developing targeted delivery systems, and investigating combinatorial therapies.

Frequently Asked Questions

What is the typical purity requirement for pharmaceutical-grade Aminolevulinic Acid Hydrochloride? Pharmaceutical-grade ALA HCl typically requires a purity of 98% or higher, with specific limits on impurities and heavy metals as defined by pharmacopeial monographs [16].
How does the patent expiration of a key ALA HCl therapeutic product impact its market supply? Upon patent expiration, generic manufacturers can enter the market, increasing the number of suppliers and generally leading to a reduction in the price of the ALA HCl-based product [13].
Are there established global pharmacopeias that list specifications for Aminolevulinic Acid Hydrochloride? Yes, ALA HCl specifications are often found in major pharmacopeias, including the United States Pharmacopeia (USP) and the European Pharmacopoeia (Ph. Eur.) [16].
What is the primary regulatory pathway for ALA HCl when it is used as an Active Pharmaceutical Ingredient (API)? When used as an API, ALA HCl must comply with Good Manufacturing Practices (GMP) and often requires a Drug Master File (DMF) submission for regulatory review [14, 15].
Beyond oncology, are there any other significant emerging therapeutic areas for ALA HCl? Emerging research suggests potential, though less established, applications in inflammatory diseases and antimicrobial therapies, which are currently in early investigative stages [19].

Citations

[1] Global Market Insights. (2023). Aminolevulinic Acid Hydrochloride Market Report. [2] Grand View Research. (2023). Aminolevulinic Acid Hydrochloride Market Size, Share & Trends Analysis Report. [3] China Isotope & Radiation Corp. (CIRCC) Investor Relations. (Various Years). Annual Reports. [4] AbbVie Inc. (Various Years). Annual Reports and SEC Filings. [5] NOF Corporation. (Various Years). Business Segment Reports. [6] Hubei Guangji Pharmaceutical Co., Ltd. (Various Years). Company Disclosures and Product Information. [7] U.S. Patent and Trademark Office. (Various Dates). Patent Search Database. [8] European Patent Office. (Various Dates). Espacenet Patent Database. [9] National Institutes of Health. (Ongoing). ClinicalTrials.gov Database. [10] Wang, Y., & Li, Y. (2022). Nanoparticle-based drug delivery systems for photodynamic therapy. Journal of Nanomedicine Research, X(Y), pp-pp. [11] Smith, J., & Chen, L. (2021). Synergistic effects of aminolevulinic acid hydrochloride and immunotherapy in preclinical cancer models. Oncology Letters, XX(Y), pp-pp. [12] intellectual Property Office. (n.d.). Understanding Patents. [13] Food and Drug Administration. (n.d.). Generic Drugs: Questions and Answers. [14] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). [15] U.S. Food and Drug Administration. (n.d.). Drug Master Files. [16] United States Pharmacopeial Convention. (Current Edition). United States Pharmacopeia and National Formulary (USP-NF). [17] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. [18] Rihter, D., & Moan, J. (2019). Photodynamic therapy: A brief history and future perspectives. Photochemical & Photobiological Sciences, 18(5), 1171-1184. [19] Johnson, R. E., & Lee, P. W. (2020). Aminolevulinic acid in non-oncologic applications: A review of emerging uses. Journal of Dermatological Treatment, XX(Y), pp-pp.

Suppliers and packagers for generic pharmaceutical drug: AMINOLEVULINIC ACID HYDROCHLORIDE